On Tuesday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), subtract -2.21% and closed at $72.82 in the last trading session. The last trading range of the stock ranges between $73.56 and $75.28. The company’s Market capitalization is $97.74 Billion with the total Outstanding Shares of 1.32 billion. During the 52-week trading session the minimum price at which share price traded, registered at $73.56 and reached to max level of $111.11. Gilead Sciences, Inc. (GILD) recently declared it has reached a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat VL in key endemic countries, counting Bangladesh, Ethiopia, India, Nepal, South Sudan and Sudan.
VL, also known as kala-azar, is the world’s second-deadliest parasitic infectious disease and affects up to 300,000 people annually in resource-limited countries.
“This new partnershipcomes at the right time as we gear up to support endemic countries in the Eastern Africa sub-region and South-East Asia to eliminate visceral leishmaniasis as a public health problem by or before 2020,” said Dr. Ren Minghui, WHO Assistant Director-General for HIV/AIDS, Malaria and Neglected Tropical Diseases. “During the past five years, AmBisome, donated by Gilead, allowed many countries in the Region highly endemic for VL to implement WHO’s recommended first line treatment, benefitting thousands of people.”
Morgan Stanley (NYSE:MS), dropped -1.17% and closed at $32.18 in the last trading session. The last trading range of the stock ranges between $31.95 and $32.76. During the 52-week trading session the minimum price at which share price traded, registered at $21.16 and reached to max level of $35.74. Investment funds managed by Morgan Stanley Global Private Equity (MSPE) declared recently that they have accomplished an investment in 24 Seven, Inc., one of North America’s leading creative and digital human capital administration firms. MSPE is partnering with the founder, Celeste Gudas, and the current administration team who will remain in place and retain a noteworthyequity stake.
24 Seven is one of North America’s preeminent human capital administration firms specializing in the placement of freelance and full-time creative, marketing and digital talent. Through a network of nine U.S. offices and two international offices, the company delivers advertising, creative, marketing and interactive / digital professionals for freelance and permanent placements. Clients include a combination of corporate marketing departments and marketing agencies. Morgan Stanley Global Private Equity believes 24 Seven attracts and places high quality talent through a consultative relationship driven approach, and has demonstrated consistently strong growth and increasing profitability.
Adam Shaw, Executive Director of Morgan Stanley Global Private Equity, said, “24 Seven is an exceptional, high-growth player in the attractive creative and digital staffing end market. Morgan Stanley Global Private Equity was exclusively positioned to evaluate the opportunity on a proprietary basis and we, together with the founders, believe Morgan Stanley Global Private Equity is the ideal partner to continue 24 Seven’s impressive growth.”